This report is designed for companies and decision-makers seeking actionable insights on market size, growth, trends, and competitive strategies to drive expansion and success in the Afrezza industry.
How has the afrezza market size changed in recent years, and what is the outlook ahead?
The afrezza market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to the focus on improving patient adherence, preference for patient-centric treatment, market entry by new players, development of rapid-acting insulin, and enhancement in product efficacy.
The afrezza market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to expansion into emerging markets, rising healthcare infrastructure, integration with CGM, supportive regulatory environment, and awareness campaigns. Major trends in the forecast period include D2C advertising, personalized diabetes care, advancements in inhalers, alternative insulin delivery systems, and innovative diabetes management solutions.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19863&type=smp
What are the top economic and technological drivers pushing afrezza market growth?
The increase in the prevalence of diabetes is expected to propel the growth of the afrezza market going forward. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels resulting from insufficient insulin production, impaired insulin action, or both. Diabetes is rising due to increasing rates of obesity, sedentary lifestyles, unhealthy diets, an aging population, urbanization, genetic predisposition, and greater awareness and diagnosis of the condition. Afrezza is essential for diabetes treatment as it quickly controls post-meal blood sugar spikes, preventing complications and ensuring effective glucose management. For instance, in March 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, in March 2023, the percentage of people with type 1 diabetes in England receiving 8 care processes at GP practices participating in the NDA rose to 43.8%, up from 35.2% in 2022. Therefore, the increase in the prevalence of diabetes drives the afrezza market.
Increasing Healthcare Spending Drives Demand For Afrezza
The rise in healthcare expenditure is expected to propel the growth of the afrezza market going forward. Healthcare expenditure refers to the total amount of financial resources spent on medical services, healthcare infrastructure, pharmaceuticals, and healthcare-related activities. Healthcare expenditure is rising due to factors such as an aging population, increasing prevalence of chronic and lifestyle-related diseases, advances in medical technology, and greater access to healthcare services. Healthcare expenditure for Afrezza, an inhaled insulin therapy, focuses on the cost of treatment, including medication, administration devices, and ongoing monitoring, aiming to improve diabetes management efficiency. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government agency, total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared to a growth rate of 0.9% in 2022. Additionally, total long-term health and social care expenditure increased by 2.8% in real terms in 2022. Therefore, the increase in healthcare expenditure drives the afrezza market.
How is the afrezza market segmented by product, application, and end-user?
The afrezza market covered in this report is segmented –
1) By Indication: Type 1 Diabetes; Type 2 Diabetes
2) By Distribution Channel: Hospitals And Clinics; Retail Pharmacies; Specialty Pharmacies
3) By End User: Adult Patients; Geriatric Patients
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/afrezza-global-market-report
What evolving trends are creating new opportunities in the afrezza market?
The key trend in the Afrezza market is focusing on developing technically advanced products by carrying out detailed studies regarding the product and diabetes. Afrezza is used to control Type 1 Diabetes using insulin inhalers. For instance, in June 2023, MannKind Corporation, a US-based biopharmaceutical company, launched an INHALE-3 study. INHALE-3 is a 17-week randomized controlled trial with a 13-week extension carried out to address the most important unmet need today in adults living with Type 1 Diabetes.
Which leading companies are dominating the afrezza market landscape?
Major companies operating in the afrezza market include Mannkind Corporation
Which geographic areas are expected to offer the highest growth opportunities in theafrezza market?
North America was the largest region in the afrezza market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the afrezza market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Afrezza Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19863
Need Customized Data On Afrezza Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=19863&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
